Disclosure: Dr. Kuti currently serves on the advisory boards/panels of AstraZeneca, Elan, and Pfizer; as a consultant to AstraZeneca, Elan, Pfizer, and Wyeth; receives grants/research support from AstraZeneca, Pfizer, and Wyeth; and serves on the speaker’s bureaus of AstraZeneca, Elan, Pfizer, Merck and Wyeth. He intends to discuss the increased dosages as well as varied infusion times for cefepime, imipenem, ciprofloxacin, levofloxacin, meropenem, piperacillin / tazobactam and fluoroquinolones in his presentation.

Clinical Content Reviewer: Juan Dumois, MD

Learning Objectives: As a result of attending this presentation, participants will be able to:

Assess emerging trends in gram-positive and gram-negative resistance to antibiotics

Describe antibiotic pharmaco-dynamic concepts and how they can be applied to current antibiotic dosing strategies to optimize clinical outcomes

Commercial Support: No

Minimum System Requirements

While the presentations may be viewable on systems that don't meet these criteria, we recommend that you use a computer that meets the following standards: